Michael J. Eckrich

Hematology | Oncology

600 Highland Ave
Madison, WI 53792

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Alemtuzumab, Fludarabine, Melphalan, and Thiotepa Conditioning for Transplantation in Inborn Errors of Immunity.

Alemtuzumab, Fludarabine, Melphalan, and Thiotepa Conditioning for Transplantation in Inborn Errors of Immunity.

Journal: Transplantation and cellular therapy

Published: September 27, 2025

RBC Alloimmunization Impacts Pediatric Sickle Cell Disease Transplant Outcomes and Transfusion Burden: A STAR Registry Report.

RBC Alloimmunization Impacts Pediatric Sickle Cell Disease Transplant Outcomes and Transfusion Burden: A STAR Registry Report.

Journal: American journal of hematology

Published: September 25, 2025

Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel.

Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel.

Journal: Blood advances

Published: April 01, 2025

Impact of Different Definitions of Vaso-Occlusion on Efficacy Assessments in Sickle Cell Disease Clinical Trials.

Impact of Different Definitions of Vaso-Occlusion on Efficacy Assessments in Sickle Cell Disease Clinical Trials.

Journal: Advances in therapy

Published: December 19, 2024

Exagamglogene Autotemcel for Severe Sickle Cell Disease.

Exagamglogene Autotemcel for Severe Sickle Cell Disease.

Journal: The New England journal of medicine

Published: April 25, 2024

Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series

Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series

Journal: Haematologica

Published: January 12, 2024

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease.

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease.

Journal: Blood

Published: November 17, 2023

Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.

Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.

Journal: Nature communications

Published: August 05, 2023

Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach.

Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach.

Journal: Seminars in hematology

Published: November 11, 2022

Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance.

Long-Term Organ Function After HCT for SCD: A Report From the Sickle Cell Transplant Advocacy and Research Alliance.

Journal: Transplantation and cellular therapy

Published: July 06, 2022

Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.

Comparison of hematopoietic cell transplant conditioning regimens for hemophagocytic lymphohistiocytosis disorders.

Journal: The Journal of allergy and clinical immunology

Published: February 11, 2021

Parvovirus B19-associated graft failure after allogeneic hematopoietic stem cell transplantation.

Parvovirus B19-associated graft failure after allogeneic hematopoietic stem cell transplantation.

Journal: Cancer reports (Hoboken, N.J.)

Published: November 18, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026